Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.

Date publication

juillet 2018

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30018134

Résumé

This SafeHer subgroup analysis assessed the safety of fixed-dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2-positive early breast cancer (EBC) by body weight.

Mots clés

Asian population, Body weight, Breast cancer, Human epidermal growth factor receptor 2‐positive, Subcutaneous injections, Trastuzumab

Référence

Oncologist. 2018 Jul 17;: